Rättelse: Pressmeddelandet från 2024-10-29 med bolagets årsredovisning innehöll en felaktig version av årsredovisningen samt saknade revisionsberättelse.
Detta utskick innehåller aktuell pdf-fil med bolagets årsredovisning för räkenskapsåret 1 maj 2023 – 30 april 2024. Denna årsredovisning ersätter den tidigare publicerade årsredovisningen från oktober 29, 2024 10:40 CET.
Updaterad årsredovisning är nu publicerad och finns tillgänglig på bolagets hemsida www.phiab.com samt bifogad.
För ytterligare information, vänligen kontakta:
Anders Månsson
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.